FGL vs IDRA-21
A side-by-side research comparison of FGL and IDRA-21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | IDRA-21 |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | IDRA-21 (Benzothiadiazide AMPA PAM) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding. |
| Molecular weight | ~1,800 Da | 262.7 Da |
| Half-life | 4-8 hours | 8-12 hours (effects persist 48-72h) |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | High (oral) |
| Typical dose | 1-5 mg/kg (research) | 10-30 mg |
| Frequency | Daily or every other day | 2-3x per week |
| Route | Subcutaneous | Oral |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
IDRA-21 reported benefits
- AMPA receptor potentiation
- Enhanced memory consolidation
- Improved learning speed
- Long-lasting effects
- Oral bioavailability
Related comparisons
Research and educational reference only. Not medical advice.